Key Points
- CFO Adam Laponis sold 8,057 shares of Twist Bioscience at an average price of $188.88, generating approximately $1.52 million. The sale was made to cover tax withholding obligations tied to vested equity awards, leaving him with 100,576 shares.
- Twist Bioscience reported 23.2% year-over-year revenue growth to $118.38 million, exceeding estimates, but missed quarterly EPS expectations and continues to operate at a loss.
- The stock was trading near its 52-week high, with a market capitalization of about $12.85 billion. Analysts’ consensus rating was “Moderate Buy,” although the consensus price target of $115.27 was well below the share price cited in the article.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 655 shares of the business's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $200.00, for a total value of $131,000.00. Following the transaction, the chief executive officer directly owned 613,044 shares in the company, valued at $122,608,800. This trade represents a 0.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Twist Bioscience Stock Up 8.7%
Shares of NASDAQ:TWST opened at $205.00 on Tuesday. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $207.90. The stock has a market cap of $12.85 billion, a P/E ratio of -92.34 and a beta of 2.19. The business has a fifty day moving average of $138.77 and a two-hundred day moving average of $93.53. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analysts' expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm's revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.33 EPS. On average, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on TWST shares. Barclays boosted their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an "overweight" rating in a report on Wednesday, June 24th. BWS Financial restated a "sell" rating and set a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Guggenheim lifted their price target on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a "buy" rating in a research report on Thursday. UBS Group started coverage on Twist Bioscience in a report on Wednesday, September 9th. They issued a "neutral" rating and a $144.00 price objective on the stock. Finally, Robert W. Baird increased their price objective on Twist Bioscience from $113.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 4th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average price target of $115.27.
Read Our Latest Research Report on TWST
Institutional Trading of Twist Bioscience
Several institutional investors and hedge funds have recently bought and sold shares of the stock. QRG Capital Management Inc. acquired a new position in Twist Bioscience in the second quarter valued at about $277,000. Engineers Gate Manager LP purchased a new position in Twist Bioscience during the second quarter worth about $3,333,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Twist Bioscience during the second quarter valued at about $99,000. Allworth Financial LP increased its position in shares of Twist Bioscience by 54.9% during the second quarter. Allworth Financial LP now owns 601 shares of the company's stock valued at $62,000 after acquiring an additional 213 shares during the last quarter. Finally, Nykredit A S purchased a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $283,000.
Key Headlines Impacting Twist Bioscience
Here are the key news stories impacting Twist Bioscience this week:
- Positive Sentiment: Analyst price-target increase: Leerink raised its target for Twist Bioscience from $120 to $160, signaling improved expectations for the company’s growth outlook. Leerink raises target for Twist Bioscience stock from USD 120 to USD 160
- Positive Sentiment: Revenue growth: Twist reported 23% year-over-year revenue growth in its latest quarterly results. Revenue exceeded analyst expectations, supporting the investment case despite the company’s continuing losses. Twist Bioscience stock reports 23 percent revenue growth
- Positive Sentiment: Breakout momentum: The stock reached a new 52-week high, reflecting strong recent investor demand and reinforcing its market momentum. Twist Bioscience Reaches New 52-Week High
- Positive Sentiment: Biotech-sector interest: Twist is among the biotechnology stocks that have surged within Cathie Wood’s ARK Genomic Revolution ETF, potentially attracting additional momentum-oriented investors. Cathie Wood’s ARKG is crushing her other ETFs
- Neutral Sentiment: Insider sales: CEO Emily Leproust, CFO Adam Laponis, CAO Robert Werner, SVP Paula Green and insider Dennis Cho collectively sold shares. The transactions were made under a pre-arranged trading plan or to cover tax withholding on vested equity awards, reducing their ownership but providing limited evidence of discretionary bearish selling.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.
The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
